Join our daily newsletter At The Bell to receive exclusive market insights
- Optiscan launches vet-first microscopic imaging device.
- Company brings its first clinical device to market.
- InSpecta creates a new in-house imaging capability for veterinary practices.
- Being showcased to vets, specialists, industry decision-makers.
Optiscan Imaging (ASX:OIL) has commenced the United States launch of InSpecta, its veterinary-first microscopic imaging device, providing it with access to a US$15.87 billion market. The milestone comes after the company successfully submitted its regulatory dossier to the U.S. FDA Centre for Veterinary Medicine.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Optiscan is now able to commence commercial sales activity in the U.S., representing a pivotal milestone in the company’s transition from a technology and product developer to a commercial enterprise.
The company’s CEO and MD, Dr Camile Farah, said InSpecta will be launched and showcased at the American Veterinary Medical Association (AVMA) Convention CY26 in Anaheim, California, providing direct exposure to a wide subset of veterinary clinicians, specialists and practice decision-makers.
“Optiscan InSpecta has been designed specifically for veterinary practices servicing this large and growing US market. It will deliver veterinarians immediate cellular insight at the point of care, allowing them to offer advanced imaging capability in-house,” Dr Farah said.
“The US launch of InSpecta validates the maturity of our imaging platform and establishes a repeatable regulatory and commercial pathway for other already revealed products that utilise our proprietary imaging technology.
“It represents one important step in Optiscan’s transition into a commercial-stage medical technology company – and more such steps are expected to follow as we continue to progress multiple human patient studies involving our other devices.”
The product is designed to address the gap between clinical examination and laboratory-based diagnostics by delivering real-time cellular imaging within the veterinary workflow, creating opportunities for improved patient care, greater workflow efficiency and new in-house service offerings.
According to a Grand View Research-prepared report, the U.S. veterinary services market was valued at approximately US$15.87 billion in CY24, and is now projected to grow strongly through to CY33.
OIL steady at 13.5¢. Mkt cap $140.9M.
Join the discussion: See what HotCopper users are saying about Optiscan Imaging Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
